Within Subjects Experimental Design for Healthy Subjects (HS)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Vanderbilt University, Nashville, TN
Healthy Subjects (HS)
Target and Stimulus - Behavioral
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

Using a noninvasive eye tracker, we will measure how participants move their eyes to objects arrayed on a computer screen. Participants will be asked to find one element among many.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: During 1-2 hour experimental session

Hour 2
Eye Tracking Data
Response Data

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Within Subjects Experimental Design
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Within Subjects Experimental Design · No Placebo Group · N/A

Within Subjects Experimental Design
Behavioral
Experimental Group · 1 Intervention: Target and Stimulus · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: during 1-2 hour experimental session

Trial Background

Prof. Thomas J. Palmeri, Distinguished Professor of Psychology
Principal Investigator
Vanderbilt University
Closest Location: Vanderbilt University · Nashville, TN
Photo of vanderbilt university medical center  1Photo of vanderbilt university medical center  2Photo of vanderbilt university medical center  3
1993First Recorded Clinical Trial
4 TrialsResearching Healthy Subjects (HS)
397 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.